tbuckley/cabot-search huggingface dataset:
Whether to Intubate During Cardiopulmonary Resuscitation
Authors: Derek C. Angus
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cost per Treatment Success of Thrombopoietin Receptor Agonists Vs "Watch and Rescue" Strategy for Treating Adult Non-Splenectomized Patients with Chronic Immune Thrombocytopenia: A US Payer Perspective
Authors: Xiaoyan Li, Anjali Sharma, Xinke Zhang, Marco Campioni, Kelly Fust, Junji Lin, Anju Parthan, Xuena Wang, Richard Zur, Karynsa Cetin, Melissa Eisen
Journal: Blood (2015)
Monoclonal Antibodies to a VWF-A2 Decapeptide with the C-Terminal Residue Tyr1605, Generated by ADAMTS13 Cleavage, Develop a Highly Sensitive ELISA for Its Activity and Characterize Upshaw-Schulman Syndrome.
Authors: Seiji Kato, Masanori Matsumoto, Tomomi Matsuyama, Hisahide Hiura, Yoshihiro Fujimura
Journal: Blood (2005)
Washing Stem Cells Cryopreserved in Dimethyl Sulfoxide (DMSO) before Infusion Prevents DMSO-Related Side Effects with Little Loss of CD34 Positive Cells and Prompt Engraftment.
Authors: Calvin Chen, Shanta Sharma, Howard Doo, Alberto Reynafarje, Bita Jallilzeinali, Tsiporah B. Shore, Michael W. Schuster
Journal: Blood (2004)
Neonatal-Perinatal Medicine
Journal: JAMA (1999)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Treatment of Relapse of AML and MDS after Allogeneic Stem Cell Transplantation Using Low-Dose Chemotherapy, Donor PBSC and GM-CSF: Final Results from a Prospective, Multicenter Phase II Trial by the German Cooperative Transplant Group.
Authors: Christoph Schmid, Johanna Tischer, Matthias Stelljes, Michael Schleuning, Rainer Schwerdtfeger, Ute Hegenbart, Joerg Schubert, Wichard Vogel, Berd Gruhn, Christiane Lallinger, Georg Ledderose, Martin Bornhaeuser, Joachim Kienast, Hans-Jochem Kolb
Journal: Blood (2007)
Antiphospholipid Syndrome: Clinical Characteristics of Patients and Affected Family Members From Multiplex Families.
Authors: Thomas L. Ortel, Fatih Cagri Sarikaya, Ahmet Alptekin, Karen E. Hansen, Robert A.S. Roubey, Anjali Sharathkumar, Robert W. Hoffman, Margaret Pericak-Vance, Jeffery Vance, Susan Hahn, Silke Schmidt
Journal: Blood (2009)
A “Master Regulatory Cis-element” Governs the Hematopoietic Stem/Progenitor Cell Compartment, Vascular Integrity, and Cardiovascular Development
Authors: Kirby D Johnson, Myung-Jeom Ryu, Meghan E Boyer, Sunduz Kelez, Jing Zhang, Youngsook Lee, Emery H Bresnick
Journal: Blood (2011)
Clinical Outcome of 96 Post-Transplant Lymphoproliferative Disease Patients in a Renal Transplant Cohort
Authors: Adriana M. Damasco Penna, Joao Garibaldi Junior, Guilherme Fleury Perini, Egyla M Cavalcanti, Marina P Cristelli, Adriana Bruscato, Jose Osmar Medina Pestana, Gisele W. B. Colleoni, Jose Pedro Zampieri Filho, Rodrigo Vaez, Otavio C. G. Baiocchi, Jose Orlando Bordin
Journal: Blood (2015)
Clinical Characteristics and Outcome of 20 Imatinib Mesylate Resistant Patients with T315I BCR-ABL Mutation.
Authors: Wan-Seok Kim, Il-Young Kweon, Soo Hyun Kim, Hyun Gyung Goh, Jeong Lee, Se Eun Jung, Dongho Kim, Sa-Hee Park, Ji-Sun Lim, Ha-Na Kim, Dong-Wook Kim
Journal: Blood (2007)
Shared decision making in low risk chest pain: looking ahead
Authors: David R Vinson, Dustin W Ballard, Dustin G Mark, Uli K Chettipally
Journal: BMJ (2017)

We commend Hess and colleagues for studying shared decision making,1 which is best suited for forks in the road, where neither course is clearly superior.23 This currently seems to be the case for patients with low risk chest pain in the …
Direct Evidence of Multilineage Differentiation and Self-Renewal Division of Individual Human Hematopoietic Stem Cell Clones In Vivo.
Authors: Takashi Yahata, Shizu Yumino, Hiroko Miyatake, Uno Tomoko, Yin Sheng, Yukari Muguruma, Mamoru Ito, Hiroyuki Miyoshi, Shunichi Kato, Tomomitsu Hotta, Kiyoshi Ando
Journal: Blood (2005)
Analysis of Readmission After Autologous HCT: Predictive Factors and Clinical Consequences
Authors: Sanjay R. Mohan, Lisa Rybicki, Stephen D. Smith, Robert Dean, Brad Pohlman, John William Sweetenham, Matt Kalaycio, Ronald Sobecks, Steven Andresen, Edward A. Copelan, Brian J. Bolwell
Journal: Blood (2010)
Study of Causes of Death in Patients with Myelodysplastic Syndrome: A Single Institution Experience
Authors: Julia Montoro, Teresa Vallespi, Esther Sancho, Olga Salamero, Laura Lopez-Andreoni, Carmen sanchez-Morata, Mayda Navarrete, Margarita Ortega, Sabela Bobillo, Noelia Valdez, Francesc Bosch, David Valcárcel
Journal: Blood (2011)
Hemodynamic instability and Horner’s syndrome following a labour lumbar neuraxial block: A warning sign of a potentially lethal event?
Authors: Daryl Irving Smith, Jennifer L. Chiem, Spencer Burk, Zana Cabak Borovcanin, Nobuyuki-Hai Tran
Journal: Journal of the Royal Society of Medicine (2017)

The development of Horner’s syndrome during routine neuraxial anaesthesia suggests anatomic, technical or physiologic variance. Even more importantly, it warrants immediate cessation of the anaesthetic intervention.
Influenza A H1N1 Pandemic Infection In Onco-Hematologic Patients
Authors: Ligia Camera Pierrotti, Marcelo Bellesso, Cilmara Polido Garcia, Juliana Pereira, José Antonio Atta, Ludhmila Abrahão Hajjar, Paulo Marcelo Gehm Hoff, Dalton FA Chamone, Edson Abdala
Journal: Blood (2010)
Biomanufacturing Seamless Tubular and Hollow Collagen Scaffolds with Unique Design Features and Biomechanical Properties
Authors: Anirudha Singh, David Lee, Nikolai Sopko, Hotaka Matsui, Praveena Sabnekar, Xiaopu Liu, Jennifer Elisseeff, Mark P. Schoenberg, Kenneth Pienta, Trinity J. Bivalacqua
Journal: Advanced Healthcare Materials (2017)

A versatile process to develop designer collagen scaffolds for hollow and tubular tissue engineering applications is presented. This process creates seamless and biomechanically tunable scaffolds ranging from ureter-like microsized tubings to structures with highly customized lumens that resemble intestinal villi, fluid bladders, and alveolar sacs that together with stem cells can potentially be used in preclinical and clinical settings. As a service to our authors and readers, this journal provides supporting information supplied by the authors. Such materials are peer reviewed and may be re-organized for online delivery, but are not copy-edited or typeset. Technical support issues arising from supporting information (other than missing files) should be addressed to the authors. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Retrospective study of compassionnal treatment of gefitinib 250 mg/d in non small cell lung cancer (NSCLC). The Hopital Avicenne experience
Authors: K. Chouahnia, G. Des Guetz, T. Bouillet, J.-M. Brechot, P. Saintigny, P. Casassus, J.-F. Morere, J.-L. Breau
Journal: Journal of Clinical Oncology (2005)

7348 Background: Gefitinib (Iressa), an inhibitor of the intracellular tyrosine kinase domain, has demonstrated useful activity in advanced pre-treated NSCLC (IDEAL I/II). Methods: Patients (pts) were treated with gefitinib 250mg/day. Endpoints included time to treatment failure (TTF). Results: 33 patients were assessed: median age (range), 61 (38–82) years; male/female, 21/12; performance status (PS) 1/2, 11/22; advanced disease (III A/IIIB/IV) 1/1/29, 31 pts were treated; median number of prior chemotherapy regimens (range), 3(1–4). 31 patients were treated and evaluable for time to Failure (TTF) according to PS status: 4.8 months (PS 1) and 5 months (PS 2). Median duration of disease control (stable disease and symptom control) was 4.9 months. Median TTF for Patients with bronchoalveolar adenocarcinoma (BAC) and adenocarcinoma (n=18) was 4 months and 3 months for patients with squamous-cell carcinoma and large cell carcinoma (n= 13). One patient treated for BAC with leptomeningeal carcinomatosis was free of disease during 6 months. The most common toxicity was diarrhoea (Grade 1, 2: 6%). Acne (Grade 1: 22%). Nausea, vomiting (Grade 1: 6%). Liver cytolysis (Grade 2: 1). Dyspnea and pulmonary lymphangitis was increased for 5 patients. Number of prior chemotherapy regimens did not significantly alter survival. Conclusions: This series of patients treated with gefitinib at 250mg/day, demonstrated similar survival and symptom response according to PS status. However Pts with BAC and Adenocarcinoma seemed to benefit more than other histological subtypes. Despite low toxicity, gefitinib can benefit heavily pre-treated patients, since the number of prior chemotherapy regimens did not influence survival. No significant financial relationships to disclose.
Long-Term Results of Single-Agent Thalidomide as Initial Therapy for Asymptomatic (Smoldering or Indolent) Myeloma.
Authors: Suzanne Hayman, Morie Gertz, Martha Lacy, Angela Dispenzieri, Rafael Fonseca, Susan Geyer, Shaji Kumar, Steven Zeldenrust, Stephen Russell, John Lust, Robert Kyle, Philip Greipp, Thomas Witzig, S. Vincent Rajkumar
Journal: Blood (2006)
The Humanized Anti-CD40 Antibody SGN-40 Inhibits Tumor Growth in LAGκ-1A, a CD40+ Mouse Model of Human Multiple Myeloma.
Authors: Richard A. Campbell, Melinda S. Gordon, Eric Sanchez, Haiming Chen, Lauren Turker, Olivia Trac, Mingjie Li, Shen Pang, Benjamin Bonavida, Jonathan Said, Jonathan G. Drachman, James R. Berenson
Journal: Blood (2006)
Monocyte-Derived Microparticles Improve Hemostasis in Factor VIIIDeficient Mice: Exploring the Role of PSGL-1/P-Selectin.
Authors: Peter L. Gross, Nima Vaezzadeh, Lori Ivicic, Ran Ni, Bruno Esposito, Xufang Bai, Ali Akram
Journal: Blood (2008)
Cofilin-2 Phosphorylation and Sequestration in Myocardial Aggregates
Authors: Khaushik Subramanian, Davide Gianni, Cristina Balla, Gabriele Egidy Assenza, Mugdha Joshi, Marc J Semigran, Thomas E Macgillivray, Jennifer E Van Eyk, Giulio Agnetti, Nazareno Paolocci, James R Bamburg, Pankaj B Agrawal, Federica Del Monte
Journal: Journal of the American College of Cardiology (2015)
Inherited Loss of Samsn1 Contributes to Increased Risk of MGUS and MM through Effects on Multiple Cell Types, Including B-Cells, Transformed Myeloma Cells, and Macrophages
Authors: Sarah Amend, William C Wilson, Liang Chu, Daniel Serie, Celine M Vachon, Lan Lu, Xinming Su, Michelle A Hurchla, Dingyan Wang, Pengyuan Liu, Ravi Vij, Graham A Colditz, Katherine N Weilbaecher, Michael H. Tomasson
Journal: Blood (2014)
AMD3100 Signals Via the Nervous System, Inducing Release to the Circulation of Bone Marrow SDF-1, Which Is Crucial for Progenitor Cell Mobilization.
Authors: Ayelet Dar, Alexander Kalinkovich, Neta Netzer, Raanan Margalit, Amir Schajnovitz, Francoise Baleux, Melania Tesio, Isabelle Petit, Tsvee Lapidot
Journal: Blood (2006)
pak2a Mutations Cause Cerebral Hemorrhage in Redhead Zebrafish.
Authors: David A. Buchner, Jordan A. Shavit, Fengyun Su, Jennifer S. Yamaoka, Makoto Kamei, Beth Mcgee, Andrew W. Hanosh, Brant M. Weinstein, David Ginsburg, Susan E. Lyons
Journal: Blood (2006)
Efficacy and comparison of antimalarials in cutaneous lupus erythematosus subtypes: a systematic review and meta-analysis
Authors: F. Chasset, J.-D. Bouaziz, N. Costedoat-Chalumeau, C. Francès, L. Arnaud
Journal: British Journal of Dermatology (2017)

The antimalarials (AMs) hydroxychloroquine (HCQ) and chloroquine (CQ) have demonstrated variable cutaneous response rates in cutaneous lupus erythematosus (CLE). We sought to assess the global cutaneous response rates to HCQ and CQ, with respect to CLE subtypes, based on previously published studies. We performed a systematic review and meta‐analysis of studies published in MEDLINE, Embase and the Cochrane Library between 1965 and December 2015. The proportions of responders to AMs according to CLE subtypes were extracted from individual studies and pooled using random‐effects or fixed models. The odds ratio (OR) was used as the measure of association to compare the response rates between CLE subtypes and AMs. Among 1990 courses of treatment with AMs from 31 included studies, the overall response rate to AMs was 63% [95% confidence interval (CI) 55–70], with important statistical heterogeneity across the included studies. HCQ had a higher overall efficacy than CQ, but this was not significant (OR 1·48, 95% CI 0·98–2·23). The response rate to AMs was different between CLE subtypes, ranging from 31% (95% CI 20–44) for chilblain lupus to 91% (95% CI 87–93) for acute CLE. The response was significantly higher for acute CLE than for subacute CLE and intermittent CLE. In case of failure of monotherapy with AM, the combination of quinacrine with HCQ or CQ seemed effective, whereas too little data were available to assess the efficacy of the switch to another AM agent. Wide discrepancies in cutaneous response to AMs are observed between CLE subtypes. A specific therapeutic approach considering CLE subtypes may improve CLE management.
A Sensitive ALK Immunohistochemistry Companion Diagnostic Test Identifies Patients Eligible for Treatment with Crizotinib
Authors: Trish Thorne-Nuzzo, Crystal Williams, Alice Catallini, June Clements, Shalini Singh, James Amberson, Kim Dickinson, Zoran Gatalica, Steffan N. Ho, Isabell Loftin, Abigail McElhinny, Penny Towne
Journal: Journal of Thoracic Oncology (2017)

The availability of high-quality, rigorously validated diagnostic tests that can be broadly implemented is necessary to efficiently identify patients with anaplastic lymphoma kinase (ALK)-positive NSCLC who can potentially benefit from treatment with crizotinib. Here we present data on the recently approved Ventana ALK (D5F3) CDx Assay (Ventana Medical Systems, Tucson, AZ), the only immunohistochemistry (IHC)-based assay linked to treatment outcome.NSCLC specimens prospectively tested for anaplastic lymphoma receptor tyrosine kinase gene (ALK) status by flourescent in situ hybridization (FISH) in the PROFILE 1014 clinical trial of crizotinib versus chemotherapy (N = 1018, including 179 ALK-positive and 754 ALK-negative specimens) were evaluated using the ALK (D5F3) CDx assay. Hazard ratios for progression-free survival comparing crizotinib and chemotherapy for ALK IHC-positive patients and ALK FISH-positive patients, as well as for concordance with the enrollment ALK FISH assay, were determined.Results from both assays were obtained for 933 cases. Percent positive, negative, and overall agreement rates were 86.0% , 96.3%, and 94.3%, respectively. There were 53 discrepant cases, of which 25 were ALK FISH-positive/ALK IHC-negative and 28 were ALK FISH-negative/ALK IHC-positive. The hazard ratios using observed outcomes were 0.401 for ALK FISH-positive/ALK IHC-positive cases and 0.407 for all ALK FISH-positive cases tested with ALK IHC versus 0.454 for all ALK FISH-positive cases enrolled in the trial. Outcome data for ALK FISH-negative/ALK IHC-positive cases were not available for analysis. Between-reader agreement rates for ALK IHC involving three independent laboratories exceeded 98%.The ALK (D5F3) CDx assay is a stand-alone companion diagnostic test for identification of patients for treatment with crizotinib. This automated assay provides an effective option to accurately and rapidly identify patients with ALK-positive NSCLC. The simple binary scoring algorithm results in high reader-to-reader precision.
Mutations of cMYC Exon 2 Are a Rare but Recurrent Abnormality in Adult Patients with Acute Myeloid Leukemia (AML)
Authors: Sylvia Herold, Michael Kramer, Christoph Röllig, Matthias Kuhn, Thoralf Stange, Uwe Platzbecker, Johannes Schetelig, Hubert Serve, Gerhard Ehninger, Christian Thiede
Journal: Blood (2015)
Lymphoproliferative Disease in Wiskott-Aldrich Syndrome: Analysis of the French National Registry of Primary Immunodeficiencies
Authors: Morgane Cheminant, Nizar Mahlaoui, Danielle Canioni, Celine Desconclois, Olivier Hermine, Marlène Pasquet, Marion Malphettes, Yves Bertrand, Stephane Blanche, Alain Fischer, Felipe Suarez
Journal: Blood (2014)
Effective Combination Therapies for B-cell Lymphoma Predicted by a Virtual Disease Model
Authors: Wei Du, Rebecca Goldstein, Yanwen Jiang, Omar Aly, Leandro Cerchietti, Ari Melnick, Olivier Elemento
Journal: Cancer Research (2017)

The complexity of cancer signaling networks limits the efficacy of most single-agent treatments and brings about challenges in identifying effective combinatorial therapies. In this study, we used chronic active B-cell receptor (BCR) signaling in diffuse large B-cell lymphoma as a model system to establish a computational framework to optimize combinatorial therapy in silico We constructed a detailed kinetic model of the BCR signaling network, which captured the known complex cross-talk between the NFκB, ERK, and AKT pathways and multiple feedback loops. Combining this signaling model with a data-derived tumor growth model, we predicted viability responses of many single drug and drug combinations in agreement with experimental data. Under this framework, we exhaustively predicted and ranked the efficacy and synergism of all possible combinatorial inhibitions of eleven currently targetable kinases in the BCR signaling network. Ultimately, our work establishes a detailed kinetic model of the core BCR signaling network and provides the means to explore the large space of possible drug combinations. Cancer Res; 77(8); 1818-30. ©2017 AACR.
Benda-BEAM High-Dose Therapy Prior to Auto-SCT Is Effective in Resistant/Relapsed DLBCL
Authors: Alessandro Isidori, Stefano Guidi, Potito Rosario Scalzulli, Attilio Olivieri, Emanuele Angelucci, Saveria Capria, Francesca Patriarca, Barbara Castagnari, Francesco Angrilli, Daniele Vallisa, Gerardo Musuraca, Andrea Mengarelli, Piero Galieni, Gaudio Francesco, Patrizia Tosi, Pier Luigi Zinzani, Alberto Bosi, Donatella Baronciani, Nicola Cascavilla, Barbara Guiducci, Cristina Clissa, Elisa Gabucci, Marco Rocchi, Federica Loscocco, Giuseppe Visani
Journal: Blood (2015)
Prognostic Significance of Venous Thromboembolic Events in Disseminated Germ Cell Cancer Patients
Authors: Enrique Gonzalez-Billalabeitia, Daniel Castellano, Nora Sobrevilla, Josep Guma, David Hervas, Maria I. Luengo, Jorge Aparicio, Alfonso Sanchez-Muñoz, Begoña Mellado, Alberto Saenz, Claudia Valverde, Antonio Fernandez, Mireia Margeli, Ignacio Duran, Sara Fernandez, Javier Sastre, Silverio Ros, Pablo Maroto, Ray Manneh, Pablo Cerezuela, Alberto Carmona-Bayonas
Journal: JNCI Journal of the National Cancer Institute (2016)

Disseminated germ cell cancers are at high risk of developing thromboembolic complications. We evaluated the prognostic value of venous thromboembolic events (VTE) in disseminated germ cell cancer.Patients with germ cell cancer receiving upfront platinum-containing chemotherapy between 2004 and 2014 were pooled from the Spanish Germ Cell Cancer Group (SGCCG) registry and reviewed for the presence of VTE. Results were validated in an independent international group of patients. We used a penalized Cox proportional hazards model including VTE as a time-varying covariate to identify and validate prognostic factors. All statistical tests were two-sided.The SGCCG registry identified 416 patients from 14 referral institutions. With a median follow-up of 49 months, VTEs were observed in 9% of patients (n = 38). Events occurred at diagnosis, during chemotherapy, and after chemotherapy in 2.6%, 5.0%, and 1.4% of patients, respectively. VTE was associated with shorter progression-free survival (PFS; hazard ratio [HR] = 2.29, 95% confidence interval [CI] = 1.18 to 4.47, P = .02) and overall survival (OS; HR = 5.14, 95% CI = 2.22 to 11.88, P < .001). In multivariable analysis, the effect was consistent in the intermediate-risk group, both for PFS (HR = 9.52 95% CI = 2.48 to 36.58, P < .001) and OS (HR = 12.84, 95% CI = 2.01 to 82.02, P = .007). VTE at diagnosis is also an adverse prognostic variable for progression-free survival (HR = 4.64, 95% CI = 2.04 to 10.54, P < .001) and for overall survival (HR = 6.28, 95% CI = 1.68 to 17.10, P = .01). These results were validated in an independent international cohort that included 241 patients from four hospitals.VTE is an independent adverse prognostic factor in disseminated germ cell cancers, in particular for the intermediate prognostic group of the International Germ Cell Cancer Collaborative Group classification. The presence of VTE at diagnosis has also prognostic significance and should be further explored in future prognostic classifications.
Sequential Analysis By Next Generation Sequencing of 18 Genes in Polycythemia Vera and Essential Thrombocythemia Reveals a Association Between Mutational Status and Clinical Outcome after 3-Year Follow-up
Authors: Damien Luque Paz, Aurelie Chauveau, Caroline Buors, Jean-Christophe Ianotto, Francoise Boyer, Laura Samaison, Claude Ferec, Cedric Le Marechal, Paul Gueguen, Valerie Ugo
Journal: Blood (2015)
Gene Mutations and Minimal Residual Disease (MRD) As Predictors of Remission Duration in Adults with Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) Treated with High-Dose Cytarabine (HDAC) - First Results of the Prospective French Intergroup CBF-2006 Trial
Authors: Eric Jourdan, Nicolas Boissel, Odile Blanchet, Aline Renneville, Christian Recher, Emmanuel Raffoux, Pascale Cornillet-Lefebvre, Jean-Michel Cayuela, Jacques Delaunay, Arnaud Pigneux, Eric Delabesse, Claude-Eric Bulabois, Céline Berthon, Cécile Pautas, Norbert Vey, Bruno Lioure, Xavier Thomas, Nathalie Contentin, Edouard Randriamalala, Nathalie Fegueux, Marie-Christine Béné, Julie Lejeune, Philippe Guardiola, Claude Preudhomme, Norbert Ifrah, Hervé Dombret
Journal: Blood (2011)